Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model

Table 3 In vivo pharmacodynamic parameters of nine generics and the innovator product of amikacin

Amikacin	AdjR²	S_y\|x	E _max	SE	ED ₅₀	SE	N	SE	BD	SE	1LKD	SE	2LKD	SE	P value
Amikacin	AdjR²	S_y\|x	E _max	SE	ED ₅₀	SE	N	SE	BD	SE	1LKD	SE	2LKD	SE	(CFA)
BMS (innovator)	0.97	0.37	6.58	0.40	272	44.6	1.02	0.12	144	12.7	266	19.9	490	40.8	NA
Carlon	0.93	0.65	5.58	0.33	160	27.0	2.01	0.49	132	17.3	190	28.6	288	55.8	0.055
FormasG	0.98	0.36	5.65	0.19	216	19.6	2.01	0.27	169	16.7	242	17.7	357	23.9	0.013
Gencol	0.99	0.24	5.10	0.14	122	11.0	2.26	0.43	110	8.30	157	15.5	248	37.1	0.001
Genven	1.00	0.17	5.36	0.07	209	13.2	3.35	0.31	185	11.9	232	13.6	301	17.8	<0.0001
Pisa	0.98	0.38	5.45	0.22	96	14.1	1.36	0.22	77	9.70	133	16.5	257	40.2	0.001
Quimicol	0.98	0.41	5.53	0.22	241	30.4	2.61	0.56	208	27.9	275	30.1	380	43.2	0.004
Scalpi	0.98	0.38	5.65	0.36	324	48.8	1.35	0.24	228	26.4	384	36.6	684	78.3	0.004
Serpharma	0.99	0.22	5.58	0.17	343	23.6	1.76	0.20	261	17.4	395	21.0	624	39.0	<0.0001
Zokumey	0.95	0.51	5.25	0.24	145	25.7	1.57	0.35	117	18.7	191	30.1	347	68.5	0.044

AdjR ² adjusted coefficient of determination, S _y|x standard error of the estimate, CFA curve fitting analysis, E _max maximum effect, SE standard error, ED ₅₀ effective dose to kill 50 % of E _max, N slope, BD bacteriostatic dose, 1LKD and 2LKD 1- and 2-log kill dose, respectively

ISSN: 1756-0500